Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on buprenorphine at analgesic doses for severe suicidal ideation in major depressive episodes
2024-512445-17-00Phase 2Authorised
- Sponsor
- CHU Nîmes
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of buprenorphine in major depressive disorder (MDD), bipolar disorder (BD) and suicidal ideation (3 arms), sponsored by CHU Nîmes. Primary endpoint: Primary: SSI score at Day 7. Planned start May 2024; status: authorised.
02
Drugs
buprenorphine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)suicidal ideation
Beyond the preview
Go deeper on 2024-512445-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512445-17-00.